Human Chitotriosidase: a Sensitive Biomarker of Sarcoidosis

Bargagli, Elena; Bennett, David; Maggiorelli, Claudia; Sipio, Pasquale Di; Margollicci, Maria; Bianchi, Nicola; Rottoli, Paola

doi:10.1007/s10875-012-9754-4

Cited by 85 publications

(91 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lipid accumulation promotes gene expression in macrophages, affecting the inflammatory process that occurs in atherogenesis [33] . Higher concentrations of chitotriosidase have been reported in the serum of patients with atherosclerosis than in controls (55-fold increase) as well as in sarcoidosis patients [29][30][31][32] . Chitinase 1 plays a role as inflammatory and profibrotic molecule in both diseases, suggesting that it may be a useful disease biomarker and indicator of atherosclerotic plaque formation, as well as in pulmonary granulomatous inflammation [34][35][36] .…”

Section: Chitotriosidase In Atherosclerosis and Sarcoidosismentioning

confidence: 97%

“…Atherosclerosis is associated with accumulation of lipids in artery walls after deposition of LDL cholesterol and fibrous matrix. In the early stage of this disease, monocytes differentiate into foam cells (lipidloaded macrophages generated by massive uptake of modified LDL) that take part in inflammatory responses and tissue remodeling in the arterial intima (vessel lumen narrowing and intimal thickening associated with increased risk of thrombosis) [29][30][31][32] . Lipid accumulation promotes gene expression in macrophages, affecting the inflammatory process that occurs in atherogenesis [33] .…”

Section: Chitotriosidase In Atherosclerosis and Sarcoidosismentioning

confidence: 99%

See 1 more Smart Citation

Increased Risk of Atherosclerosis in Patients with Sarcoidosis

Bargagli¹,

Rosi²,

Lavorini³

et al. 2017

Pathobiology

Self Cite

View full text Add to dashboard Cite

Sarcoidosis is a systemic granulomatous disease of unknown etiology. Recent studies demonstrated that its pathogenesis is related with enhanced oxidative stress (protein carbonylation and lipid peroxidation) and alterations in the circulating lipid profile. Alterations of lipid metabolism (including the reduction in high-density lipoprotein cholesterol levels and apolipoprotein A1 concentrations) induce plasma membrane, bronchial and lung capillary endothelial cell damage in sarcoidosis patients. Dyslipidemia is associated with increased oxidative stress, diminished overall antioxidative protection and increased risk for atherosclerosis. Very recently increased cardiovascular biomarkers (in particular alterations of lipoprotein A and d-dimer concentrations) were observed in sarcoidosis patients, mainly in those with a high risk of atherosclerosis. Chitotriosidase, a biomarker of sarcoidosis activity and macrophage activation, is increased in serum and bronchoalveolar lavage fluid of patients with sarcoidosis as well as in patients with atherosclerosis. Lipidomics and other recent methodologies allowed the discovery of proteins involved in lipid metabolism and sarcoidosis pathogenesis, such as serum amyloid A, a biomarker of sarcoidosis activity, involved in innate immune response, inflammation and apolipoprotein metabolism. In this review lipid metabolism alteration and atherosclerosis risk in sarcoidosis patients were discussed in order to contribute to this novel and interesting research topic.

show abstract

Section: Chitotriosidase In Atherosclerosis and Sarcoidosismentioning

confidence: 97%

Section: Chitotriosidase In Atherosclerosis and Sarcoidosismentioning

confidence: 99%

Increased Risk of Atherosclerosis in Patients with Sarcoidosis

Bargagli¹,

Rosi²,

Lavorini³

et al. 2017

Pathobiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Consequently CHIT-1 is used as a highly specific biomarker for lysosomal storage disorder [14]. Later the levels of this enzyme were found elevated in Niemann-Pick diseases [15], but also in other pathological conditions including β-thalassaemia [16], sarcoidosis [17], multiple sclerosis [18], atherosclerosis [10] and in parasitic infections such as plasmodium falciparum malaria [19]. Interestingly, other investigations have suggested that CHIT-1 may be involved in the progression of nonalcoholic steatohepatitis [20,21] and could have a crucial role even in pathological conditions, such as coronary artery disease [22], acute ischemic stroke [23] cerebrovascular dementia (CVD) and Alzheimer's disease (AD) [24].…”

Section: Introductionmentioning

confidence: 99%

Comparison of YKL-39 and CHIT-1 expression during macrophages differentiation and polarization

Rosa¹,

Tibullo²,

Malaguarnera³

et al. 2013

MRI

View full text Add to dashboard Cite

The chitinase-like proteins YKL-39 (chitinase 3-like-2) and Chitortriosidase (CHIT-1) are members of the chitinases family. YKL-39 expression has been associated with osteoarthritis, whereas CHIT-1 activity is regarded as a biochemical marker of macrophage activation. So far, the physiological or pathological role of YKL-39 in the inflammation is still poorly understood. We compared YKL-39 and CHIT-1 modulation during monocyte to macrophage transition and polarization. Gene expression analysis was investigated by real-time PCR from mRNA of human monocytes obtained from buffy coat of healthy volunteers, from mRNA of polarized macrophages to classically activated macrophages (or M 1 ), obtained by interferon-γ and lipopolysaccharide exposure, and from mRNA of alternatively activated macrophages (or M 2 ) obtained by interleukin-4 exposure. We demonstrated different variations of YKL-39 and CHIT-1 production during macrophages polarization. CHIT-1 levels gradually increase in the course of the time with a peak of expression between the fifth and the seventh day of culture. In contrast, YKL-39 expression was unaltered in the diverse stage of HMMs differentiation, but increased significantly in M 1 polarized macrophages and reverted to base levels in M 2 polarized macrophages. These findings indicated that the function of YKL-39 is much more restricted and selective than that exerted by CHIT-1.

show abstract

“…We did not consider persistent disabling symptoms such as fatigue, small-fibre neuropathy, cognitive dysfunction, depression and impaired quality of life, which may be at the forefront for many patients with sarcoidosis [40][41][42][43][44][45]. We did not consider new biomarkers [46] or FDG-PET, which is used only in certain circumstances [47,48]. Currently, the main uses for FDG-PET are in 1) helping find a site for biopsy in difficult cases, 2) investigation of cardiac sarcoidosis [48], 3) searching for active pulmonary lesions in advanced fibrotic pulmonary sarcoidosis, and 4) searching for metabolic activity in patients with persistent disabling symptoms and normal biomarkers, i.e.…”

Section: Discussionmentioning

confidence: 99%

Management of sarcoidosis in clinical practice

et al. 2016

View full text Add to dashboard Cite

Sarcoidosis is a systemic disease of unknown cause with very diverse presentation, outcome, severity and need for treatments. While some presentations may be very typical, for many patients, the presentation is nonspecific, with shared associations with other diseases at times being by far more frequent or misleading, which can be a cause of significant delay and often several consultations before a diagnosis of sarcoidosis can be confirmed. This is particularly the case when pulmonary manifestations are in the forefront. The diagnosis relies on three well-known criteria. In clinical practice, these criteria are not easily implemented, particularly by physicians without expertise in sarcoidosis, which can lead to a risk of either under-or over-diagnosis. Qualifying the presentation according to sarcoidosis diagnosis is essential. However, it is often not easy to classify the presentation as typical versus compatible or compatible versus inconsistent. Further investigations are needed before any other hypothesis is to be considered. It is important to detect events and to determine whether or not they are indicative of a flare of sarcoidosis. Eventually, treatment needs to be related to the correct indications. The evaluation of the efficacy and safety of treatments is crucial. To address such issues, we present five emblematic cases that illustrate this. @ERSpublications Showing emblematic cases is the best way to illustrate the multiple conditions to deal with for managing sarcoidosis http://ow.ly/10A5Yv

show abstract

Human Chitotriosidase: a Sensitive Biomarker of Sarcoidosis

Abstract: Chitotriosidase proved to be a biomarker with good sensitivity and specificity that is easily detected in serum. It can be proposed in clinical practice to identify progressive patients requiring close follow-up, to detect relapses and to evaluate the effects of therapy.

Cited by 85 publications

References 29 publications

Increased Risk of Atherosclerosis in Patients with Sarcoidosis

Increased Risk of Atherosclerosis in Patients with Sarcoidosis

Comparison of YKL-39 and CHIT-1 expression during macrophages differentiation and polarization

Management of sarcoidosis in clinical practice

Contact Info

Product

Resources

About